Not only did patient lose weight slowly about 50 pounds a year but he developed the tools to keep it off. The key is portion control. He weighs and measures everything he eats. If he is eating a piece of chicken he doesnt assume its four ounces, because nine times out of 10 its more. Wife and patient also learned to plan ahead. If theyre going out to dinner, they eat less early in the day. Being in it together is a real plus. They got rid of everything that was bad like ice cream so that one wasnt eating it when the other couldnt.
They met with a nutritionist who fine-tuned what theyd already learned. For instance, she suggested not eating carbohydrates during evening meals. Patient takes inspiration from weekly Weight Watchers meetings, and in three years has never missed one. That really helped. People were genuinely happy when he did well and they wanted him to succeed. Another change is working out. He took a while just to be able to, but now he exercise for about 45 minutes five days a week. One of the biggest differences this time around was patients overall attitude about weight loss, particularly when he hit plateaus. People tell you youll lose one-to-two pounds a week, but he had periods for three months where he didnt lose a pound. It was so frustrating. It gets on the scale knowing hed lost weight and not be down a pound. Then the day hes least expect it, hed find he lost weight. It completely screws up your mind and you have to be ready for it. Patient is more than ready to maintain his weight loss success. He has a lot of self-esteem and confidence now. He feels normal.
New evidence suggests that an experimental weight-loss drug helps people keep off the weight they initially lost for up to two years. In a study involving 3,045 people, subjects who took a daily 20 milligram dose of the drug rimonabant lost over 17 pounds on average within the first year of treatment, while maintaining their new weight throughout the second year. Subjects who switched to another pill after the first year gained nearly all of the weight back during the second year, a common result in most studies of weight-loss drugs. The findings were presented by the studys primary investigator, chief of endocrinology at St. Lukes Roosevelt Hospital Center in New York, at this years annual scientific meeting of the American Heart Association. The drug blocks receptors in the brain that control appetite and also has drawn attention for its apparent positive effects on waist size, cholesterol and blood sugar. The Food and Drug Administration may approve rimonabant by late 2005 or early 2006. While heart experts find these results encouraging, they stress that more information on the drug is needed, and that exercise and healthy diets are still crucial to losing weight.